Holen Sie sich die Stockscreener-App
14.15
1.80%
0.25
Handel nachbörslich:
14.15
Schlusskurs vom Vortag:
$13.90
Offen:
$14.23
24-Stunden-Volumen:
2.17M
Relative Volume:
1.08
Marktkapitalisierung:
$2.18B
Einnahmen:
$276.98M
Nettoeinkommen (Verlust:
$-59.46M
KGV:
-35.49
EPS:
-0.3987
Netto-Cashflow:
$-48.95M
1W Leistung:
+6.55%
1M Leistung:
-12.71%
6M Leistung:
+7.77%
1J Leistung:
+68.05%
1-Tages-Spanne:
$13.94
$14.51
1-Wochen-Bereich:
$12.97
$14.51
52-Wochen-Spanne:
$6.675
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
14.15 | 2.14B | 276.98M | -59.46M | -48.95M | -0.3987 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies (ADPT) president Rubinstein sells $769k in stock - Investing.com UK
Adaptive Biotechnologies (ADPT) COO sells 57K shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $255,594.60 in Stock - MarketBeat
Adaptive Biotechnologies COO Rubinstein sells $762k in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies COO Rubinstein sells $762k in ADPT stock - Investing.com
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares - Stock Titan
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
ADPT (NASDAQ: ADPT) lists 140,666 RSUs and 329,600 PSUs in Rule 144 filing - Stock Titan
Insider sales at Adaptive Biotechnologies (NASDAQ: ADPT) include 122,523 RSUs - Stock Titan
18,672 RSUs registered for sale by filer (ADPT) via Morgan Stanley - Stock Titan
Chad Robins lists multiple ADPT share sales in Form 144 (ADPT) - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Adaptive Biotechnologies Corporation $ADPT Shares Sold by Braidwell LP - MarketBeat
Adaptive Biotechnologies CFO Piskel sells $245,910 in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies director Griffin sells $214,130 in stock By Investing.com - Investing.com India
Insider Sell: Michelle Griffin Sells 15,394 Shares of Adaptive B - GuruFocus
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 18,672 Shares of Stock - MarketBeat
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells 470,167 Shares of Stock - MarketBeat
Adaptive Biotechnologies’ president Rubinstein sells $2.37 million in ADPT stock - Investing.com
Adaptive Biotechnologies director Griffin sells $214,130 in stock - Investing.com
Adaptive Biotechnologies CCO Bobulsky sells $544k in ADPT stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Executives Sell Shares to Cover Tax Obligations - TradingView
Adaptive Biotechnologies’ chief scientific officer sells $6.19 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CFO Piskel sells $245,910 in shares - Investing.com
Adaptive Biotechnologies’ chief people officer Lo sells $430k in stock - Investing.com Canada
Adaptive Biotechnologies’ chief people officer Lo sells $430k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief commercial officer sells $831k in stock - Investing.com
Adaptive Biotechnologies’ chief scientific officer sells $6.19 million in stock - Investing.com
Adaptive Biotechnologies’ chief commercial officer sells $831k in stock By Investing.com - Investing.com UK
Adaptive Biotechnologies Executives Sell Shares for Tax Obligations - TradingView
Adaptive Biotechnologies Hits Day Low of $12 Amid Price Pressure - Markets Mojo
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap UpWhat's Next? - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 9.9%Here's Why - MarketBeat
Francis Lo reports multiple 10b5-1 share sales for ADPT (NASDAQ: ADPT) - Stock Titan
Michelle Griffin sells 48,044 ADPT shares (ADPT) for $735K - Stock Titan
ADPT (Adaptive Biotechnologies) NonCurrent Deferred Revenue : $1.0 Mil (As of Dec. 2025) - GuruFocus
Piper Sandler reiterates Adeptus Biotechnologies stock rating at overweight By Investing.com - Investing.com India
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 19,460 Shares of Stock - MarketBeat
Adaptive Biotechnologies Executive Sells Over $1.2 Million in Company Stock - TradingView
Piper Sandler reiterates Adeptus Biotechnologies stock rating at overweight - Investing.com
Lo Francis, chief people officer at Adaptive Biotechnologies, sells $574k in ADPT By Investing.com - Investing.com South Africa
Lo Francis, chief people officer at Adaptive Biotechnologies, sells $574k in ADPT - Investing.com Nigeria
Adaptive Biotechnologies (ADPT) HR chief offloads shares to cover RSU taxes - Stock Titan
Adaptive Biotechnologies Exec Sells Shares to Cover Tax - TradingView
Do Insider Sales Align With Adaptive Biotechnologies' (ADPT) MRD-Driven Momentum and Long-Term Strategy? - simplywall.st
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Director at Adaptive Biotechnologies (ADPT) receives 15,625-share award - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) grants 44,063 shares to Chief People Officer - Stock Titan
Adaptive Biotechnologies (ADPT) CFO receives 61,875-share stock grant - Stock Titan
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):